Lyell Immunopharma, Inc. (LYEL) Net margin 2019–2025
Lyell Immunopharma, Inc. (LYEL) net profit margin by fiscal year — reported net income divided by reported revenue.
-762355.6%FY2025 · since FY2019: -19692.1% → -762355.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -762355.6% | -200070.3 pp |
| FY2024 | -562285.2% | -381799.1 pp |
| FY2023 | -180486.2% | -180269.9 pp |
| FY2022 | -216.2% | +2133.2 pp |
| FY2021 | -2349.5% | +286.8 pp |
| FY2020 | -2636.3% | +17055.8 pp |
| FY2019 | -19692.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More LYEL financial trends
LYEL RevenueLYEL Net incomeLYEL Gross profitLYEL Gross marginLYEL Operating incomeLYEL Operating marginLYEL Operating cash flowLYEL Free cash flowLYEL Capital expendituresLYEL Return on equityLYEL Stock buybacksLYEL Dividends paidLYEL Total assetsLYEL Total liabilitiesLYEL Shareholders’ equityLYEL overview →